3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
27
Leukemia, Myeloid, Acute
27
Leukemia
16
Myelodysplastic Syndromes
13
Myeloproliferative Disorders
4
Myelodysplastic-Myeloproliferative Diseases
4
Leukemia, Myelomonocytic, Acute
4
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
4
Leukemia, Monocytic, Acute
4
Leukemia, Megakaryoblastic, Acute
4
Leukemia, Erythroblastic, Acute
4
Hematologic Neoplasms
4
Congenital Abnormalities
4
Leukemia, Myelomonocytic, Chronic
3
Anemia, Refractory, with Excess of Blasts
3
Primary Myelofibrosis
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hodgkin Disease
2
Blast Crisis
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neutropenia
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Interventions
venetoclax
27
Cyclophosphamide
18
Azacitidine
13
fludarabine
12
ibrutinib
10
Busulfan
10
fludarabine phosphate
9
Rituximab
8
Mycophenolic Acid
8
Methotrexate
8
Cytarabine
8
Whole-Body Irradiation
7
Peripheral Blood Stem Cell Transplantation
7
Clofarabine
7
Therapeutics
6
Melphalan
6
Antilymphocyte Serum
6
obinutuzumab
5
Tacrolimus
5
Surveys and Questionnaires
5
Stem Cell Transplantation
5
Mesna
5
Exercise
5
Cyclosporine
5
vosaroxin
4
trametinib
4
thymoglobulin
4
ruxolitinib
4
ponatinib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Tretinoin
×
Other hematologic neoplasm
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled